Previous close | 0.9400 |
Open | 0.9399 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 800 |
Day's range | 0.9200 - 0.9400 |
52-week range | 0.6300 - 4.9500 |
Volume | |
Avg. volume | 20,407 |
Market cap | 8.116M |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5800 |
Earnings date | 09 Jun 2023 - 11 Jun 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CHICAGO, May 26, 2023--Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company"), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of the C
CHICAGO, May 19, 2023--Exicure, Inc., announced today it received a notice of non-compliance from Nasdaq Stock Market LLC.
CHICAGO, May 04, 2023--Exicure has invested in Cyworld Z Co. Ltd. through the purchase of $1 million aggregate principal amount of convertible bonds issued by Cyworld Z.
CHICAGO, April 27, 2023--Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company’s board of directors (the "Board"). Mr. Kim succeeds Dr. Matthias Schroff, who yesterday steppe
CHICAGO, March 27, 2023--Exicure, Inc., reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress.
CHICAGO, February 24, 2023--Exicure today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. effective February 24, 2023.
CHICAGO, December 14, 2022--Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
CHICAGO, November 14, 2022--Exicure reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress.
CHICAGO, September 26, 2022--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.
CHICAGO, September 01, 2022--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.
CHICAGO, August 15, 2022--Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.
CHICAGO, July 20, 2022--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share minimum
CHICAGO, June 29, 2022--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business tomor